Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2022-08-02 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于对外担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of external guarantees provided by the company to its subsidiaries and controlled companies. It includes specifics about guarantee amounts, parties involved, financial data of the guaranteed companies, guarantee agreements, and board opinions. The document is not a financial report like an annual or interim report, nor is it a call transcript or earnings release. It is a regulatory announcement about financing guarantees, which fits best under the category of Capital/Financing Update (CAP). The document length is over 10,000 characters and contains substantive financial and operational details about guarantees, not just a brief notice or a report publication announcement. Therefore, the classification is CAP with high confidence.
2022-08-02 Chinese
昆药集团关于华润三九医药股份有限公司收到《经营者集中反垄断审查不实施进一步审查决定书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Corporation regarding the receipt of a decision from the State Administration for Market Regulation about an antitrust review related to a share transfer agreement involving a change in control. It references previous announcements and approvals needed for the transaction but does not contain financial statements or detailed financial data. The document is short (1271 characters) and serves as a regulatory update on the status of a merger-related approval process. It is not a full merger filing or a detailed financial report but an official regulatory announcement about the antitrust review decision. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-07-07 Chinese
昆药集团独立董事关于公司十届六次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the unlocking of restricted stock under a 2021 restricted stock incentive plan. It discusses compliance with relevant regulations and the legitimacy of the stock unlocking event. This is a governance-related document focusing on board-level approval and compliance with stock incentive plans, not a full financial report or earnings release. It is not a report publication announcement or a certification letter but a formal board/management related opinion. Therefore, it fits best under Board/Management Information (MANG). The document length is short and specific to board matters, supporting this classification.
2022-06-10 Chinese
北京德恒（昆明）律师事务所关于昆药集团2021年限制性股票激励计划第一个解除限售期解除限售条件成就的法律意见
Regulatory Filings
2022-06-10 Chinese
昆药集团十届六次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the supervisory board (监事会) of Kunming Pharmaceutical Group regarding the resolution passed in their meeting about the unlocking of restricted stock under the 2021 restricted stock incentive plan. It includes voting results and confirms compliance with relevant regulations. The content is about a board/management decision related to stock incentive plans, not a full financial report or earnings release. It is not a report publication announcement or a certification. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management decisions regarding stock incentives.
2022-06-10 Chinese
昆药集团关于2021年限制性股票激励计划第一个解除限售期解除限售暨上市公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the first unlocking and listing of restricted shares under the 2021 restricted stock incentive plan. It details the approval and implementation of the incentive plan, the conditions for lifting the restrictions on the shares, the number of shares unlocked, and the legal opinion confirming compliance with relevant laws and regulations. The document is a formal disclosure about the unlocking and listing of restricted stock, which is a capital change event affecting the company's share capital structure. It is not a financial report, earnings release, or management discussion, but rather a specific announcement about share capital changes related to stock incentives. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length (5710 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2022-06-10 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.